Glutamine to Treat Cancer - Quick Reference Sheet
evipedia.ai ← Back

Glutamine to Treat Cancer

Created on 06/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

In cancer, glutamine is used mainly to ease treatment harms rather than to fight the tumor. The most dependable benefit is reducing severe mouth and throat soreness during chemotherapy and radiation, and its safety as a supplement is strong. Because many tumors feed on glutamine, supplying it could in theory nourish the cancer. (Full Review)

Protocol

Dose
10–30 g/day
Oral, in divided doses (two to three times per day)
Form & Administration
Powder in water
Swish-and-swallow oral suspension to bathe the mouth lining for mucositis
Timing
Through treatment
Begin at or shortly before chemotherapy/radiation and continue through the course
Time to effect
Mucositis & Diarrhea
Over weeks
Used prophylactically from the start of treatment; protection accrues over the treatment course rather than immediately

Benefits

Contraindications
  • Active glutamine-avid gastrointestinal tumors (e.g., gastric or colorectal cancer involving the gut lumen)
  • Significant hepatic encephalopathy or severe renal impairment (e.g., advanced cirrhosis, Child-Pugh Class C; severe chronic kidney disease)
  • Enrollment in a glutamine-targeting drug trial
    •
Key Interactions
  • Glutamine-antagonist cancer drugs (e.g., DRP-104, telaglenastat)
  • Chemotherapy agents (general)
  • Lactulose and ammonia-lowering therapy (in hepatic insufficiency)
  • Antioxidant supplements (e.g., N-acetylcysteine)
    •

Risk & Side Effects

  • High: Generally excellent tolerability
    •
  • Medium: Theoretical tumor-fueling in glutamine-avid cancers
    •
  • Low: Gastrointestinal discomfort; glutamate-related neurological effects
    •
  • Speculative: Accumulation risk in hepatic or renal impairment
    •

Monitoring

Marker Target Why
Liver function (ALT, AST) ALT/AST within mid-normal limits Glutamine metabolism involves the liver; screen capacity before high-dose use
Kidney function (eGFR, BUN) eGFR ≥ 90 mL/min/1.73m²; BUN low-normal Metabolism yields ammonia/urea; impaired clearance raises accumulation concern
Blood ammonia Within normal limits Glutamine breakdown generates ammonia; relevant in hepatic impairment
Plasma glutamine Within normal range Low baseline identifies the most plausible responders (conditional deficiency)
Nutritional markers (albumin, prealbumin) Albumin ≥ 4.0 g/dL; prealbumin normal Tracks nutritional status that glutamine aims to support
C-reactive protein (CRP) < 1.0 mg/L (low) General inflammation marker that may fall with effective mucosal/gut support

Cadence: Baseline before high-dose use, then at each treatment cycle or every 1–4 weeks during active therapy, with side-effect grading at each clinical visit

Qualitative Assessment

  • Mouth and throat comfort — reduced pain, ulceration, and difficulty eating or swallowing (mucositis severity)
  • Bowel function — frequency and severity of treatment-related diarrhea
  • Skin condition — redness, soreness, or breakdown in the radiation field (radiodermatitis)
  • Energy and appetite — ability to maintain food intake and weight through treatment
  • Treatment continuity — whether side effects are mild enough to avoid dose delays or interruptions
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.